PET Scan (Positron Emission Tomography): Metabolic and Cancer Imaging

Positron emission tomography (PET) is a nuclear medicine imaging technique that maps metabolic activity in living tissue rather than simply depicting anatomy. This page explains the physical and biochemical mechanisms behind PET imaging, the clinical scenarios in which it is ordered, how it compares to anatomical modalities, and the regulatory and safety framework governing its use in the United States. Understanding PET's scope is central to any comprehensive picture of medical imaging at large.

Definition and scope

PET scanning produces functional images by detecting gamma-ray pairs emitted when a radiotracer — a biologically active molecule tagged with a positron-emitting radionuclide — undergoes annihilation within tissue. The most widely used radiotracer is fluorodeoxyglucose labeled with fluorine-18 (¹⁸F-FDG), a glucose analog that accumulates preferentially in cells with high metabolic rates, including most malignant tumors, active inflammatory foci, and certain regions of the brain.

The U.S. Food and Drug Administration (FDA) regulates radiopharmaceuticals as drugs under 21 CFR Part 212 (FDA Current Good Manufacturing Practice for PET Drugs), which establishes manufacturing standards for positron emission tomography drugs. The Centers for Medicare & Medicaid Services (CMS) separately determines reimbursement coverage criteria for specific PET indications, including oncologic staging and myocardial viability assessment (CMS NCA for FDG PET).

PET is distinct from structural modalities such as CT or MRI in that the primary signal reflects biochemistry, not density or proton relaxation. Because of this, PET is frequently fused with CT or MRI — producing PET/CT or PET/MRI hybrid studies — to co-register metabolic findings with precise anatomical landmarks. The American College of Radiology (ACR) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) jointly publish practice parameters governing hybrid PET/CT and PET/MRI protocols (SNMMI/ACR Practice Parameters).

How it works

PET image acquisition follows a defined sequence of physical and technical steps:

1. Radiotracer administration — The patient receives an intravenous injection of a radiolabeled compound (most commonly ¹⁸F-FDG, with a physical half-life of approximately 109.8 minutes).
2. Uptake phase — The patient rests quietly for 45–90 minutes to allow tissue distribution and cellular uptake. Blood glucose levels are typically managed below 200 mg/dL, as elevated glucose competes with ¹⁸F-FDG for uptake.
3. Annihilation event detection — Positrons emitted by ¹⁸F travel 1–2 millimeters before annihilating with an electron, producing two 511 keV gamma photons traveling in opposite directions at 180 degrees.
4. Coincidence detection — A ring of detectors surrounding the patient captures these photon pairs in coincidence windows typically 6–12 nanoseconds wide, localizing the annihilation event.
5. Image reconstruction — Iterative reconstruction algorithms (such as ordered subsets expectation maximization, OSEM) convert coincidence data into three-dimensional maps of radiotracer concentration.
6. Attenuation correction — CT transmission data in a PET/CT system corrects for photon attenuation through tissue, improving quantitative accuracy.
7. Standardized uptake value (SUV) calculation — Radiotracer concentration is normalized to injected dose and patient weight, producing an SUV that allows semi-quantitative comparison across scans and institutions.

The nuclear medicine physician or radiologist interprets the fused metabolic and anatomical dataset. Preparing appropriately for the exam — including fasting, blood glucose management, and activity restriction — is described separately on the preparing for PET scan page.

Common scenarios

¹⁸F-FDG PET/CT is ordered across a defined set of well-supported clinical indications:

Oncology — The dominant application. PET/CT is used for initial staging, restaging after treatment, detection of recurrence, and assessment of treatment response in malignancies including non-small cell lung cancer, lymphoma (Hodgkin and non-Hodgkin), colorectal cancer, head and neck squamous cell carcinoma, melanoma, and esophageal cancer. CMS coverage for FDG PET in oncology is codified in National Coverage Determination 220.6.

Neurology — ¹⁸F-FDG PET characterizes hypometabolic patterns in Alzheimer disease and frontotemporal dementia. Amyloid PET tracers — including ¹⁸F-florbetapir (Amyvid), ¹⁸F-florbetaben (Neuraceq), and ¹⁸F-flutemetamol (Vizamyl) — directly image amyloid plaque burden. All three received FDA approval between 2012 and 2014.

Cardiology — Myocardial viability assessment using ¹⁸F-FDG PET or rubidium-82 (⁸²Rb) perfusion PET guides decisions about revascularization in patients with ischemic cardiomyopathy.

Infection and inflammation — ¹⁸F-FDG PET/CT is increasingly used to identify occult infection, large-vessel vasculitis (including giant cell arteritis), and fever of unknown origin.

For an expanded discussion of how oncologic imaging fits within the broader field, see cancer screening and surveillance imaging.

Decision boundaries

PET is not universally superior to anatomical imaging, and specific limitations define where it is and is not appropriate.

PET versus CT/MRI

Contraindications and limitations

Pregnancy is a relative contraindication; the American College of Radiology (ACR) Manual on Contrast Media and radiation-risk guidance classify fetal dose from ¹⁸F-FDG as requiring case-by-case risk-benefit analysis. Active nursing requires a 12-hour interruption of breastfeeding following ¹⁸F-FDG administration, per SNMMI guidance.

False-positive ¹⁸F-FDG uptake occurs in inflammatory and infectious processes, post-surgical sites, brown adipose tissue, and physiologic bowel activity. False-negative results are documented in low-grade malignancies (well-differentiated thyroid cancer, prostate adenocarcinoma, bronchoalveolar carcinoma) that do not significantly upregulate glucose metabolism.

Radiation dose from a combined ¹⁸F-FDG PET/CT study ranges from approximately 7 to 14 millisieverts (mSv) depending on CT technique (ACR–AAPM–SPR Practice Parameter for PET/CT), a range comparable to diagnostic CT abdomen/pelvis. The regulatory and dosimetric context applicable to all nuclear medicine and radiology procedures is detailed under regulatory context for radiology.

Non-FDG tracers are expanding PET's scope: ⁶⁸Ga-DOTATATE (Lutathera diagnostic companion) for somatostatin receptor imaging in neuroendocrine tumors received FDA approval in 2016; ¹⁸F-PSMA-1007 and ⁶⁸Ga-PSMA-11 target prostate-specific membrane antigen for prostate cancer staging. Each tracer has distinct uptake physiology and a corresponding approved or investigational indication.

References

• U.S. Food and Drug Administration — 21 CFR Part 212: Current Good Manufacturing Practice for Positron Emission Tomography Drugs
• Centers for Medicare & Medicaid Services — National Coverage Determination 220.6: FDG PET for Oncologic Conditions
• Society of Nuclear Medicine and Molecular Imaging (SNMMI) — Clinical Practice Guidelines
• American College of Radiology — ACR–AAPM–SPR Practice Parameter for the Performance of PET/CT
• [U.S. FDA — Approved Amyloid PET Imaging Agents](https://www.fda.gov/drugs/resources-information-approved-drugs/h

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)